iRegene Therapeutics Raises 210M Yuan in Series C1 for AI-Powered Cell Therapy Platform

iRegene Therapeutics completed a 210 million yuan ($29 million) Series C1 financing round to advance its AI-driven chemical induction platform for universal cell therapies targeting age-related diseases.